Journal
AMINO ACIDS
Volume 39, Issue 1, Pages 233-242Publisher
SPRINGER WIEN
DOI: 10.1007/s00726-009-0433-6
Keywords
Synthetic peptide; Stability; Prostate cancer; Kallikrein-related peptidase 3; KLK3; Prostate specific antigen; PSA
Categories
Funding
- Finnish Funding Agency for Technology and Innovation (TEKES)
- University of Helsinki, Helsinki University Central Hospital
- Finnish Cancer Foundation, the Academy of Finland [126969]
- Juselius Foundation
- Finska Lakaresallskapet
- Academy of Finland (AKA) [126969, 126969] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
Human prostate produces kallikrein-related peptidase 3 (KLK3, also known as prostate specific antigen), which is widely used as a prostate cancer marker. Proteolytically active KLK3 has been shown to inhibit angiogenesis and its expression decreases in poorly differentiated tumors. Thus, it may be possible to control prostate cancer growth with agents that stimulate the proteolytic activity of KLK3. We have earlier developed synthetic peptides, which bind specifically to KLK3 and promote its proteolytic activity. These peptides are cyclic, all containing a disulfide bridge between the N- and C-terminal cysteines. To increase the in vivo stability of the KLK3-stimulating peptide B-2, we made differently cyclized analogues by replacing both terminal cysteines and the disulfide bridge between them. A replacement consisting of gamma-amino butyric acid and aspartic acid, where the amino group from the former was linked to the main chain carboxyl group of the latter, was found to be, at high concentrations, more active than the B-2 peptide. Furthermore, as compared to the parent peptide, this analog had an improved stability in plasma and against the enzymatic degradation by KLK3. In addition, the series of analogues also provided valuable information of the structure-activity relationships of the B-2 peptide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available